N-acetyl-b-D-glucosaminidase: A potential cardiorenal biomarker with a relevant impact on ICD shock therapies and mortality.
Acetylglucosaminidase
/ metabolism
Adult
Aged
Arrhythmias, Cardiac
/ metabolism
Biomarkers
/ metabolism
Cardio-Renal Syndrome
/ diagnosis
Creatinine
/ urine
Defibrillators, Implantable
Electric Countershock
Female
Hepatitis A Virus Cellular Receptor 1
/ metabolism
Hospitalization
Humans
Male
Middle Aged
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Predictive Value of Tests
Prognosis
Retrospective Studies
Survival Rate
Treatment Outcome
ICD shock therapies
cardiorenal syndrome
tubular markers
Journal
Nephrology (Carlton, Vic.)
ISSN: 1440-1797
Titre abrégé: Nephrology (Carlton)
Pays: Australia
ID NLM: 9615568
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
13
06
2020
revised:
05
08
2020
accepted:
09
08
2020
pubmed:
26
8
2020
medline:
30
10
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
Chronic heart failure may lead to chronic kidney disease. Previous studies suggest tubular markers N-acetyl-b-D-glucosaminidase (NAG) and Kidney-injury-molecule-1 (KIM-1) as potential markers for the cardiorenal syndrome (CRS). The prognostic value of NAG and KIM-1 regarding implantable cardioverter defibrillator (ICD) shock therapies is unknown. We included 314 patients with an ICD and collected plasma and urine samples. Urine-values of NAG and KIM-1 got related to urinary creatinine. Outcomes of interest were sustained adequate shock therapies and a combined endpoint of all-cause mortality, rehospitalisation due to congestive heart failure and adequate shock therapies. Follow up time was 32 months (IQR 6-35 months). KIM-1 and NAG were positively correlated with NT-proBNP (KIM-1: r = .34, P < .001; NAG: r = .47, P < .001). NAG was significantly elevated in patients with primary prevention compared with secondary prevention ICD indication (P = .003). According to Kaplan Meier analysis, NAG as well as NT-proBNP were significant predictors for adequate ICD shock therapies and for the combined endpoint (each P < .001). Elevated KIM-1 showed no significant differences (each P = n.s.). In multivariate cox regression analysis, NAG as well as NT-proBNP were both independent predictors for adequate ICD shock therapies as well as the combined endpoint, beside ejection fraction <35% (each P < .05). Diabetes, primary prevention ICD indication, coronary artery disease, eGFR and age were no significant predictors for both endpoints (each P = n.s.). Similar to NT-proBNP, NAG showed promising value for overall prognostication in ICD patients. Especially, NAG seems to incorporate an additional prognostic value regarding occurrence of ICD shock therapies.
Substances chimiques
Biomarkers
0
HAVCR1 protein, human
0
Hepatitis A Virus Cellular Receptor 1
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Creatinine
AYI8EX34EU
Acetylglucosaminidase
EC 3.2.1.52
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
888-896Informations de copyright
© 2020 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.
Références
Srinivasan NT, Schilling RJ. Sudden cardiac death and arrhythmias. Arrhythmia Electrophysiol Rev. 2018;7(2):111-117.
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-2867.
Wellens HJJ, Schwartz PJ, Lindemans FW, et al. Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J. 2014;35(25):1642-1651.
McKie PM, Burnett JC. NT-proBNP: the gold standard biomarker in heart failure. J Am Coll Cardiol. 2016;68(22):2437-2439.
Ronco C, House AA, Haapio M. Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus. Nat Clin Pract Nephrol. 2008;4(6):310-311.
Damman K, van Veldhuisen DJ, Navis G, et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010;96(16):1297-1302.
Jungbauer CG, Birner C, Jung B, et al. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011;13(10):1104-1110.
Jungbauer CG, Uecer E, Stadler S, et al. N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: new predictors for long-term progression of chronic kidney disease in patients with heart failure. Nephrology (Carlton). 2016;21(6):490-498.
Ichimura T, Mou S. Kidney injury molecule-1 in acute kidney injury and renal repair: a review. Zhong Xi Yi Jie He Xue Bao. 2008;6(5):533-538.
Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol. 1992;38(Suppl 1):S14-S19.
Bonventre JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant. 2009;24(11):3265-3268.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-1539.
Damman K, Masson S, Hillege HL, et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail. 2013;1(5):417-424.
Kolodziejczak M, Andreotti F, Kowalewski M, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: a systematic review and meta-analysis. Ann Intern Med. 2017;167(2):103-111.
Chapter 1: definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19-62.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
Brott DA, Adler SH, Arani R, Lovick SC, Pinches M, Furlong ST. Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers. Drug Des Devel Ther. 2014;8:227-237.
Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm. 2014;11(7):1109-1116.
Klein G, Lissel C, Fuchs A-C, et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-study. Europace. 2006;8(8):618-624.
Simsek MA, Degertekin M, Turer Cabbar A, et al. NT-proBNP levels and mortality in a general population-based cohort from Turkey: a long-term follow-up study. Biomark Med. 2018;12(10):1073-1081.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239.
Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6(3):257-260.
Lorvidhaya P, Addo K, Chodosh A, Iyer V, Lum J, Buxton AE. Sudden cardiac death risk stratification in patients with heart failure. Heart Fail Clin. 2011;7(2):157-174. vii.
Stehlik J, Feldman DS. Arrhythmias in heart failure: beyond sudden cardiac death. Curr Opin Cardiol. 2013;28(3):315-316.
Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis. 2018;25(5):382-390.
Damman K, Masson S, Hillege HL, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705-2712.
Vest RN, Gold MR. Risk stratification of ventricular arrhythmias in patients with systolic heart failure. Curr Opin Cardiol. 2010;25(3):268-275.
Beaser AD, Cifu AS, Nayak HM. Primary prevention of sudden cardiac death. JAMA. 2019;322(2):161-162.
Podrid PJ. Potassium and ventricular arrhythmias. Am J Cardiol. 1990;65(10):33E-44E. discussion 52E.
Klein L, Hsia H. Sudden cardiac death in heart failure. Cardiol Clin. 2014;32(1):135-144. ix.
Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-1230.